Literature DB >> 32255489

Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.

Sophie Perinel1,2, Manon Launay3, Élisabeth Botelho-Nevers4, Éric Diconne1, Aurore Louf-Durier1, Raphaël Lachand1, Martin Murgier1, Dominique Page1, Régine Vermesch1, Guillaume Thierry1, Xavier Delavenne2,3.   

Abstract

Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting in various concentrations. Pharmacokinetic studies are therefore needed to define the optimal dosing regimen.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-Cov2; hydroxychloroquine; intensive care; pharmacokinetic

Mesh：

Substances：

Year:  2020        PMID： 32255489      PMCID： PMC7184449          DOI： 10.1093/cid/ciaa394

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  38 in total

Review 1.  Medication use during COVID-19: Review of recent evidence.

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

2.  Bronchoalveolar lavage-detected SARS-CoV-2 infection in presence of serial negative nasopharyngeal swabs: a case report.

Authors:  Grazia Caci; Fabrizio Minervini; Carsten Fechner; Justus E Roos; Ellen C Obermann; Andrea Azzola
Journal:  Ann Transl Med       Date:  2021-04

3.  Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence.

Authors:  Konstantinos Tselios; Panagiotis Skendros
Journal:  Eur J Rheumatol       Date:  2020-05-15

4.  Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance.

Authors:  Cristhieni Rodrigues; Rodrigo S Freitas-Santos; José Eduardo Levi; Andreza A Senerchia; Ana Tarina A Lopes; Sergio R Santos; Rinaldo F Siciliano; Lígia C Pierrotti
Journal:  Int J Antimicrob Agents       Date:  2021-08-25       Impact factor: 5.283

Review 5. 

Authors:  T S Brandon Ng; Kori Leblanc; Darwin F Yeung; Teresa S M Tsang
Journal:  Can Fam Physician       Date:  2021-03       Impact factor: 3.275

6.  Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?

Authors:  Matthew M Ippolito; Charles Flexner
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

7.  Does therapeutic drug monitoring of hydroxychloroquine improve treatment outcome in intensive care unit patients with COVID-19?

Authors:  Kamer Tecen-Yucel; Elif Aras-Atik; Aygin Bayraktar-Ekincioglu
Journal:  Int J Clin Pract       Date:  2021-04       Impact factor: 2.503

8.  Coronavirus Disease 2019 (COVID-19) Pharmacologic Treatments for Children: Research Priorities and Approach to Pediatric Studies.

Authors:  Anthony J Garcia-Prats; Nicole Salazar-Austin; James H Conway; Kendra Radtke; Sylvia M LaCourse; Elizabeth Maleche-Obimbo; Anneke C Hesseling; Rada M Savic; Sharon Nachman
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

Review 9.  Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic.

Authors:  Bogna Grygiel-Górniak
Journal:  Clin Rheumatol       Date:  2021-07-03       Impact factor: 3.650

Review 10.  Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.

Authors:  Nicolas Venisse; Gilles Peytavin; Stephane Bouchet; Marie-Claude Gagnieu; Rodolphe Garraffo; Romain Guilhaumou; Caroline Solas
Journal:  Antiviral Res       Date:  2020-07-10       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.